The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Complete revascularisation in the STEMI patient: is it worth the effort?

EuroIntervention 2020;16:195-199. DOI: 10.4244/EIJV16I3A34

1. University of Leicester, University Hospitals of Leicester, NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom


Disease in a non-culprit vessel is observed in up to 50% of ST-elevation myocardial infarction (STEMI) patients. Randomised trials, such as PRAMI1, CvLPRIT2, DANAMI-3-PRIMULTI3 and Compare-Acute4, demonstrated improved composite clinical outcomes with complete revascularisation (CR). More recently, the largest study, the COMPLETE trial, showed a reduction in hard clinical endpoints (death and recurrent myocardial infarction [MI]) with CR5. Considered together with a very recently published meta-analysis6, the data strongly support CR in multivessel disease (MVD) STEMI patients and it certainly appears to be worth the effort. It is unlikely that further trials comparing complete versus incomplete revascularisation will be ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy